TaperCommunityTaperCommunity
Forums/Drug Profiles/

Xanax Tapering Guide

alprazolam

BenzodiazepineFDA 1981
Go to Community Forum

Boxed Warning

Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Risks of abuse, misuse, and addiction, which can lead to overdose and death. Physical dependence and life-threatening withdrawal reactions.

Overview

Alprazolam is a short-acting, high-potency benzodiazepine approved for anxiety disorders and panic disorder. It is the most commonly prescribed benzodiazepine in the US and has the highest abuse potential among benzodiazepines due to rapid onset and short duration.

Common Doses

0.25mg, 0.5mg, 1mg, 2mg

Formulations

Tablets: 0.25mg, 0.5mg, 1mg, 2mg; Extended-release tablets (XR): 0.5mg, 1mg, 2mg, 3mg; Orally disintegrating tablets: 0.25mg, 0.5mg, 1mg, 2mg; Oral concentrate: 1mg/mL

Pregnancy

Category D (positive evidence of risk)

Mechanism of Action

Positive allosteric modulator at GABA-A receptors. Binds to the benzodiazepine site, enhancing GABA-mediated inhibition. Its rapid onset and short half-life contribute to both its anxiolytic efficacy and high dependence liability.

Taper Notes

Very short half-life makes this the hardest benzodiazepine to taper. Inter-dose withdrawal common. Crossover to diazepam strongly recommended.

Hyperbolic Tapering Guidance

Crossover to diazepam essential for safe taper. Very short half-life causes interdose withdrawal. Never stop abruptly.

Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.

Tapering Protocol

Evidence-based phased reduction schedule. Always taper under medical supervision.

PhaseDurationNotes
Crossover to diazepam2-4 weeksStrongly recommended due to Xanax's short half-life. Your prescriber will determine equivalence and crossover schedule.
Initial diazepam reductions2-4 weeks per stepOnce stabilized on diazepam, your prescriber begins gradual reductions. Diazepam's long half-life makes each step smoother.
Middle reductions3-6 monthsProgressively smaller reductions. Liquid diazepam may be used for precision.
Final reductions3-6 monthsVery gradual approach. Work closely with your prescriber through this phase.

Withdrawal Timeline

Onset

6-12 hours after missed dose (fastest of all common benzos)

📈Peak Severity

2-4 days (acute withdrawal can be medically dangerous)

📉Resolution

2-4 weeks for acute symptoms if tapered properly

⚠️Protracted Risk

Rebound panic, cognitive impairment, agoraphobia, and depersonalization may persist 6-18 months. Xanax has the highest reported rate of protracted withdrawal among benzos.

Community Tips

Practical insights shared by members tapering Xanax. Not medical advice — always consult your prescriber.

  • 1Xanax's short half-life makes direct tapering very challenging. Discuss the diazepam crossover approach (recommended by Ashton and Maudsley) with your prescriber.
  • 2If your prescriber recommends direct tapering, ask about XR formulation — it provides a smoother plasma curve than IR.
  • 3Rebound panic attacks during Xanax taper are common and can feel indistinguishable from the original anxiety disorder. They are temporary and will resolve.
  • 4Never adjust your Xanax dose on your own — always work with your prescriber. Contact them if withdrawal symptoms are unmanageable.
  • 5Track your symptoms daily in your taper journal. This data is invaluable for your prescriber in planning pace adjustments.

Common Withdrawal Symptoms

severe anxietyinsomniaseizure riskpanic attackstremordepersonalization

Interactions & Safety

Drug Interactions

  • Opioids — FDA boxed warning: concurrent use increases risk of profound sedation, respiratory depression, coma, and death
  • CYP3A4 inhibitors (ketoconazole, itraconazole, nefazodone, fluvoxamine) significantly increase alprazolam levels
  • CYP3A4 inducers (carbamazepine, rifampin) decrease alprazolam levels

Food Interactions

  • Food does not significantly affect absorption
  • Avoid alcohol (additive CNS and respiratory depression, potentially fatal)
  • Grapefruit juice increases levels via CYP3A4 inhibition

Contraindications

  • Acute narrow-angle glaucoma
  • Concurrent ketoconazole or itraconazole
  • Known hypersensitivity to alprazolam or other benzodiazepines

Toxicity

Severe CNS and respiratory depression (especially with opioids/alcohol). Extremely high physical dependence potential. Withdrawal seizures and death possible with abrupt discontinuation. Rebound anxiety between doses.

Pharmacokinetics

ADME Profile

Absorption

Rapidly absorbed after oral administration. Bioavailability ~80–90%. Tmax 1–2 hours (IR), ~11 hours (XR). Food does not significantly affect total absorption.

Distribution

~0.9–1.2 L/kg

Metabolism

Hepatic via CYP3A4 (primary) to alpha-hydroxyalprazolam (weakly active) and a benzophenone derivative (inactive).

Elimination

Renal (~80% as metabolites). Less than 20% excreted unchanged in urine.

Protein Binding

~80%

Clearance

~1.0–1.3 mL/min/kg

Need a clinician who understands tapering?

Browse our map of deprescribing-informed providers worldwide.

Find a Deprescriber

Other Drug Profiles

Sources & References

Xanax (alprazolam) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.

Encyclopedic & chemical databases

Neutral, high-authority entity references.

Regulatory sources

Official prescribing information and safety notices.

Peer-reviewed research

Primary literature cited in this taper guide.

Deprescribing-specific resources

Clinician-facing references on tapering protocols.

Patient-advocacy & lived-experience

Long-running communities documenting withdrawal experience.

TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.